<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000979'>Purpura</z:hpo> fulminans (PF) is a life-threatening disorder characterized by <z:hpo ids='HP_0011009'>acute onset</z:hpo> of progressive <z:mp ids='MP_0011514'>cutaneous hemorrhage</z:mp>, <z:mp ids='MP_0001651'>necrosis</z:mp>, and <z:hpo ids='HP_0005521'>disseminated intravascular coagulation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> infectious PF occurs most commonly in the setting of meningococcal <z:hpo ids='HP_0100806'>sepsis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>When PF occurs in the setting of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), the catastrophic <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome (CAPS) must be ruled out because urgent therapy is required </plain></SENT>
<SENT sid="3" pm="."><plain>Plasmapheresis is effective in both cases, but immunosuppression (high-dose <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> plus <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>), although beneficial in patients with CAPS, could be harmful in patients with meningococcal PF </plain></SENT>
<SENT sid="4" pm="."><plain>The authors report here a patient with SLE who presented to the intensive care unit with meningococcal PF, <z:hpo ids='HP_0001919'>acute renal failure</z:hpo>, and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002098'>respiratory distress</z:hpo> syndrome and discuss clinical similarities and laboratory differences from CAPS </plain></SENT>
</text></document>